8,405 reports of this reaction
3.5% of all WARFARIN reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for WARFARIN, manufactured by Amneal Pharmaceuticals LLC. There are 8,405 FDA adverse event reports linking WARFARIN to DYSPNOEA. This represents approximately 3.5% of all 237,331 adverse event reports for this drug.
WARFARIN has an overall safety score of 92 out of 100. Patients taking WARFARIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among WARFARIN users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for WARFARIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 8,405 FDA reports for WARFARIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.5% of all adverse event reports for WARFARIN, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking WARFARIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.